Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ajhp/59.1.81 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic Factors Associated with 2-year Mortality in Patients with Intermittent Claudication Treated with Endovascular Therapy for Femoropopliteal Lesions: Results from the Multicenter PROCYON Study.
J Atheroscler Thromb
December 2024
Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center.
Aim: Few studies have evaluated the midterm prognosis of patients with intermittent claudication who underwent endovascular therapy (EVT) for femoropopliteal lesions. Therefore, we aimed to assess 2-year mortality and prognostic factors in these patients.
Methods: We retrospectively analyzed 947 patients who underwent EVT for intermittent claudication between January 2018 and December 2021 at eight Japanese cardiovascular centers.
The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database.
PLoS One
December 2024
Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
Objective: Cilostazol is indicated for alleviating intermittent claudication (IC) in stable-phase peripheral arterial disease (PAD) patients. Conducting data mining on adverse events (AEs) of cilostazol in the U.S.
View Article and Find Full Text PDFAim: The "2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease" provides recommendations to guide clinicians in the treatment of patients with lower extremity peripheral artery disease across its multiple clinical presentation subsets (ie, asymptomatic, chronic symptomatic, chronic limb-threatening ischemia, and acute limb ischemia).
Methods: A comprehensive literature search was conducted from October 2020 to June 2022, encompassing studies, reviews, and other evidence conducted on human subjects that was published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline. Additional relevant studies, published through May 2023 during the peer review process, were also considered by the writing committee and added to the evidence tables where appropriate.
Article Synopsis
- - The 2024 guideline focuses on managing lower extremity peripheral artery disease, providing recommendations for different patient conditions, including asymptomatic and acute limb ischemia.
- - A thorough literature review from October 2020 to June 2022 was conducted, analyzing studies published in English, with further updates considered through May 2023.
- - The updated guideline enhances the previous 2016 recommendations and introduces new strategies to ensure comprehensive care for patients suffering from peripheral artery disease.
Medical Optimization of Patients with Symptomatic Peripheral Arterial Disease.
Ann Vasc Surg
October 2024
Evans Department of Medicine/Section of Cardiovascular Medicine and Whitaker Cardiovascular Institute, Boston University Chobanian & Avedisian School of Medicine, Boston, MA. Electronic address:
Article Synopsis
- * Common symptoms of PAD, like claudication and chronic limb-threatening ischemia, significantly reduce a person's ability to function and diminish their quality of life.
- * Current treatments aim to ease symptoms, enhance life quality, and prevent serious cardiovascular issues, consisting of various medications, exercise programs, and lifestyle changes like quitting smoking.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!